Raj, R. et al. 2023. Randomized Phase III Trial Comparing Epirubicin/ Doxorubicin Plus Docetaxel and Epirubicin/ Doxorubicin Plus Paclitaxel as First Line Treatment in Women with Advanced Breast Cancer. Journal for Research in Applied Sciences and Biotechnology. 2, 3 (Jun. 2023), 55–63. DOI:https://doi.org/10.55544/jrasb.2.3.8.